



PTQ/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Do not respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

*(use as many sheets as necessary)*

Sheet

1

of

4

**Complete if Known**

Application Number

## Unassigned

Filing Date

**July 11, 2003**

**First Named Inventor**

Elisabeth DEFOSSA et al.

### Group Art Unit

Unassigned 1625

**Examiner Name**

~~Unassigned ZND AUs~~

Attorney Docket Number

**38005-0178**

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>9</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
me	A05	EP	0 221 847	A2	Ciba-Geigy AG	5/13/1987		
↑	A06	WO	97/26265	A1	Novo Nordisk A/S	7/24/1997		
↑	A07	WO	97/41097	A2	Dr. Reddy's Research Foundation	11/6/1997		
↑	A08	WO	98/08871	A1	Novo Nordisk A/S	3/5/1998		
↑	A09	WO	99/03861	A1	Novo Nordisk A/S	1/28/1999		
↑	A10	WO	99/15525	A1	Sanofi	4/1/1999		
↑	A11	WO	00/40569	A1	Alizyme Therapeutics Limited	7/13/2000		
↑	A12	WO	00/63208	A1	Novo Nordisk A/S	10/26/2000		
me	A13	WO	00/64888	A1	Aventis Pharmaceuticals	11/2/2000		

**Examiner  
Signature**

Furness N Davis

Date  
Considered

1/12/2005

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC**



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	2
-------	---

2

of

4

Attorney Docket Number

**Complete if Known**

Application Number

## Unassigned

Filing Date

**July 11, 2003**

First Named Inventor

Elisabeth DEFOSS et al.

### Group Art Unit

### Unassigned

Examiner Name

## Unassigned


Attorney Docket Number

**38005-0178**

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>0</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A14	WO	00/64876	A1	Aventis Pharmaceuticals	11/2/2000		
	A15	WO	00/66585	A1	Neurogen Corp.	11/9/2000		
	A16	WO	00/71549	A1	Knoll Aktiengesellschaft	11/30/2000		
	A17	WO	00/78312	A1	Merck & Co., Inc.	12/28/2000		
	A18	WO	01/09111	A1	Eli Lilly & Co.	2/8/2001		
	A19	WO	01/83451	A1		11/8/2001		
	A20	WO	01/85695	A1	Bristol-Myers Squibb	11/15/2001		
	A21	WO	01/91752	A1	Merck & Co., Inc.	12/6/2001		
	A22	DE	10142734	A1	Aventis Pharma Deutschland GmbH	3/27/2003		

**Examiner  
Signature\***

Date Considered

1/12/2005

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/APTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	3	of	4
-------	---	----	---

**Complete if Known**

Application Number	Unassigned
--------------------	------------

<b>Filing Date</b>	<b>July 11, 2003</b>
--------------------	----------------------

First Named Inventor	Elisabeth DEFOSS et al
----------------------	------------------------

### Group Art Unit

Examiner Name

Attorney Docket Number

**38005-0178**

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Date Considered

1/12/2005

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC



please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/616,959		
		Filing Date	July 11, 2003		
		First Named Inventor	Elisabeth DEFOSSA et al.		
		Group Art Unit	Unassigned 1625		
		Examiner Name	Unassigned ZNDAYS		
Sheet	4	of	4	Attorney Docket Number	38005-0178

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ZND	A24	A. ASAKAWA et al., "Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice", Horm. Metab. Res., 2001, pp. 554-558, Vol. 33	
	A25	P. DRUECKES et al., "Photometric Microtiter Assay of Inorganic Phosphate in the Presence of Acid-Labile Organic Phosphates", Analytical Biochemistry, 1995, p. 173-177, Vol. 230	
	A26	H.D. ENGERS et al., "Kinetic mechanism of phosphorylase a. I. Initial velocity studies", Department of Biochemistry, University of Alberta, Edmonton 7, Alberta, January 12, 1970, pp. 746-754	
	A27	DANIEL W. LEE et al., "Leptin agonists as a potential approach to the treatment of obesity", Drugs of the Future, 2001, pp. 873-881, Vol. 26, No. 9	
	A28	HIROSHI OKADA et al., "Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas", Chem. Pharm. Bull., 1994, pp. 57-61, Vol. 42, No. 1	
	A29	JAVIER SALVADOR et al., "Perspectives in the therapeutic use of leptin", Expert Opin. Pharmacother, 2001, 2001, pp. 1615-1622, Vol. 2, No. 10	
	A30	PRAVENN TYLE, "Iontophoretic Devices for Drug Delivery", Pharmaceutical Research, 1986, pp. 318-326, Vol. 3, No. 6	
	A31	H.J.F. ZUNFT et al., "Carob Pulp Preparation for Treatment of Hypercholesterolemia", Advances In Natural Therapy, September/October 2001, pp. 231-236, Vol. 18, No. 5	

Examiner Signature		Date Considered	1/12/2005
--------------------	--	-----------------	-----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



+

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

*(use as many sheets as necessary)*

Sheet	1	of	1
-------	---	----	---

**Complete if Known**

Application Number	10/616,959
Filing Date	July 11, 2003
First Named Inventor	Elisabeth DEFOSSA et al.
Group Art Unit	unassigned 1625
Examiner Name	<del>4614</del> 2NDAYLE
Attorney Docket Number	38005-0178

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Lenore A. Davis

Date Considered

1/12/2005

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D**